Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Talphera, Inc. [ACRX]

Reports for Purchase

Showing records 41 - 60 ( 176 total )

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 41

07/24/2020

Pages: 8

Zimmer Biomet Agreement Represents Low-Risk Path to Large DSUVIA Market Opportunity; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 42

07/20/2020

Pages: 3

New DOD Contract Award to Study DSUVIA Head-to-Head vs. Actiq; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 43

06/04/2020

Pages: 4

After Two Increases to Its Original Bid, AcelRx Decides to Pass on Tetraphase; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 44

06/02/2020

Pages: 7

How High Will They Go? Melinta''s Third Revision Deemed a Superior Offer, Again

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 45

05/12/2020

Pages: 9

1Q20 Recap: Recurring DoD Revenues Support DSUVIA Growth, Expansion

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 46

05/07/2020

Pages: 4

La Jolla Throws a Monkey Wrench With Its Own Offer

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 47

05/01/2020

Pages: 6

Near-Term Military Order for DSUVIA Should More Than Offset COVID-19 Impact

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 48

03/17/2020

Pages: 9

Good Deal: We See Immediate Synergies in Acquisition of Tetraphase; PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 49

01/17/2020

Pages: 3

Dropping Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 50

11/08/2019

Pages: 5

3Q Recap: Early DSUVIA Launch Is Humming; Metrics at or Above Target; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 51

10/17/2019

Pages: 3

ASA Presentation Highlights Key Advantages of DSUVIA to Healthcare Providers; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 52

08/06/2019

Pages: 5

2Q19 Recap: Focus on Access; Setting the Foundation for Growth; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 53

06/06/2019

Pages: 6

Continuing to Execute on Key Objectives for 2019; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 54

05/09/2019

Pages: 4

1Q19 Recap; Early Days, but We See Early Signs of Interest in Adopting DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 55

04/12/2019

Pages: 3

Pooled Analysis of Over 800 Patients Validates DSUVIA''s Safety in Elderly Patients; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 56

03/11/2019

Pages: 7

Very Early Days But Already Some Encouraging Signs on the DSUVIA Launch; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 57

02/01/2019

Pages: 3

Burn Symposium to Showcase the Elegant Simplicity of Non-Invasive DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 58

01/15/2019

Pages: 4

Opioid Potency and Other Revelations from a Pooled Safety Analysis of DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 59

12/12/2018

Pages: 12

Key Takeaways From Analyst Day Ahead of DSUVIA Launch; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 60

11/06/2018

Pages: 8

DSUVIA Approved; Launch Planned for 1Q19; Raise PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

// eof